Status:
UNKNOWN
The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Prostate Cancer
Eligibility:
MALE
Up to 75 years
Phase:
PHASE1
PHASE2
Brief Summary
Helical tomotherapy is being used to treat the prostate gland, local rates of spread and regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in the prostate is hyp...
Eligibility Criteria
Inclusion
- High risk localized prostate cancer
Exclusion
- Low/intermediate risk, metastatic cancer
- Patient refusal
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00126802
Start Date
April 1 2005
End Date
March 1 2017
Last Update
July 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2